Clinical trial · Observational
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center
NCT03117036CI-TRIAL-00090003recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Hodgkin | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Lymphoma, Non-Hodgkin | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Lymphoma
- description
- Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.
- interventionNames
- Drug: Chemotherapy
Primary outcomes (1)
- measure
- Response rate
- timeFrame
- 3 months after chemotherapy
- description
- response to chemotherapy
Secondary outcomes (3)
- measure
- Progression-free survival
- timeFrame
- 3 year
- description
- Time to relapse/progression or any kinds of death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas 2. 20 years 3. Patients requiring systemic chemotherapy with curative intent 4. Written informed consent Exclusion Criteria: 1. Myeloid malignancy 2. Multiple myeloma 3. Patients do not require systemic chemotherapy with curative intent
References
Publications (0)
Data not yet available
No reference posted for this study.